Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minehiko Inomata

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2024
Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047)Tetsuhiko Asao, Takehito Shukuya, Kohei Uemura, et al.
Lung Cancer (Amsterdam, Netherlands)|August 11, 2022
Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: A multicenter retrospective cohort study (NEJ-042)Yuji Minegishi, Tomoe Akagami, Makoto Arai, et al.
Targeted Oncology|April 13, 2024
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)Naoya Nishioka, Hisao Imai, Masahiro Endo, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2026
Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in JapanSatoshi Ikeda, Takashi Ogura, Toshihiro Misumi, et al.
JTO Clinical and Research Reports|October 24, 2022
Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance DataHideki Terai, Kenzo Soejima, Asanao Shimokawa, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2024
Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047)Tetsuhiko Asao, Takehito Shukuya, Kohei Uemura, et al.
Lung Cancer (Amsterdam, Netherlands)|August 11, 2022
Real-world outcomes of chemotherapy for lung cancer patients undergoing hemodialysis: A multicenter retrospective cohort study (NEJ-042)Yuji Minegishi, Tomoe Akagami, Makoto Arai, et al.
Targeted Oncology|April 13, 2024
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)Naoya Nishioka, Hisao Imai, Masahiro Endo, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2026
Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in JapanSatoshi Ikeda, Takashi Ogura, Toshihiro Misumi, et al.
JTO Clinical and Research Reports|October 24, 2022
Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance DataHideki Terai, Kenzo Soejima, Asanao Shimokawa, et al.
Pageof 7